Šalis: Australija
kalba: anglų
Šaltinis: Department of Health (Therapeutic Goods Administration)
imipramine hydrochloride, Quantity: 10 mg
Amdipharm Mercury Australia Pty Ltd
Tablet, sugar coated
Excipient Ingredients: macrogol 8000; povidone; stearic acid; hypromellose; purified talc; glycerol; magnesium stearate; titanium dioxide; maize starch; microcrystalline cellulose; iron oxide red; colloidal anhydrous silica; lactose monohydrate; sucrose; copovidone
Oral
50
Medicine Registered
(S4) Prescription Only Medicine
Major depression. Nocturnal enuresis (from the age of 5 years onwards and provided the possibility of organic causes has first been excluded).
Visual Identification: Red-brown, triangular-shaped, convex, sugar- coated tablets; Container Type: Blister Pack; Container Material: PVC/PE/PVDC/Al; Container Life Time: 5 Years; Container Temperature: Store below 30 degrees Celsius
Registered
1991-08-02
TOFRANIL ® _10 MG AND 25 MG TABLETS_ _Imipramine hydrochloride_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Tofranil. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. The information in this leaflet was last updated on the date listed on the final page. More recent information on the medicine may be available. YOU SHOULD ENSURE THAT YOU SPEAK TO YOUR PHARMACIST OR DOCTOR TO OBTAIN THE MOST UP TO DATE INFORMATION ON THE MEDICINE. Those updates may contain important information about the medicine and its use of which you should be aware. All medicines have risks and benefits. Your doctor has weighed the risks of you or your child taking this medicine against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT TOFRANIL IS USED FOR Tofranil is used to treat: 1. Depression that is longer lasting and/or more severe than the "low moods" that everyone has from time to time due to the stress of everyday life. It is thought to be caused by a chemical imbalance in parts of the brain. This imbalance affects your whole body and can cause emotional and physical symptoms such as feeling low in spirit, loss of interest in activities, being unable to enjoy life, poor appetite or overeating, disturbed sleep, loss of sex drive, lack of energy and feeling guilty over nothing. 2. Bed-wetting in people from the age of 5 years onwards if there is no physical cause for the problem (i.e. there is nothing wrong with the bladder itself). Tofranil belongs to a group of medicines called tricyclic antidepressants (TCAs). Tofranil corrects this chemical imbalance and may help relieve the symptoms of depression. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another purpose. This me Perskaitykite visą dokumentą
TOFRANIL ® 1 AUSTRALIAN PRODUCT INFORMATION TOFRANIL ® IMIPRAMINE HYDROCHLORIDE TABLET 1 NAME OF THE MEDICINE Imipramine hydrochloride 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Tofranil 10 tablets contain 10 mg imipramine hydrochloride. Tofranil 25 tablets contain 25 mg imipramine hydrochloride. Excipients with known effect: Lactose monohydrate, Sucrose For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Tofranil 10: The tablets are red-brown, triangular-shaped, convex, sugar-coated tablets printed “FT” on one side in white ink. Tofranil 25: The tablets are reddish-brown, round, biconvex, sugar-coated tablets printed “CZ” on one side in white ink. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS • Major depression. • Nocturnal enuresis (from the age of 5 years onwards and provided the possibility of organic causes has first been excluded). 4.2 DOSE AND METHOD OF ADMINISTRATION GENERAL The dosage should be determined individually and adapted to the patient's condition. In principle, every effort must be made to achieve an optimum effect while keeping the dose as low as possible and increasing the dosage cautiously, particularly when treating elderly patients, who generally show a more marked response to Tofranil than patients belonging to intermediate age groups. TOFRANIL ® 2 During treatment with Tofranil patients must be kept under close surveillance with respect to the efficacy and tolerability of the medication. MAJOR DEPRESSION Treatment in ambulatory patients: Initiate treatment with 25 mg up to three times daily. Raise the daily dosage stepwise to 150 to 200 mg. This dosage should be reached by the end of the first week and adhered to until a clear-cut improvement has occurred. The subsequent maintenance dose, which must be individually determined by cautiously reducing the dosage, usually amounts to 50 to 100 mg daily. Treatment in hospitalised patients: Initiate treatment with 25 mg three times a day. Raise the daily dosage stepwise by 25 mg, until Perskaitykite visą dokumentą